Zevra Therapeutics Inc
ZVRA8.870USD
+0.230+2.66%
收盘 12/26, 16:00（美东）报价延迟15分钟
498.65M总市值
14.70市盈率 TTM
关于 Zevra Therapeutics Inc 公司
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Zevra Therapeutics Inc简介
公司代码ZVRA
公司名称Zevra Therapeutics Inc
上市日期Apr 16, 2015
CEOMcfarlane (Neil F)
员工数量59
证券类型Ordinary Share
年结日Apr 16
公司地址1180 Celebration Boulevard
城市CELEBRATION
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编34747
电话13219393416
网址https://zevra.com/
公司代码ZVRA
上市日期Apr 16, 2015
CEOMcfarlane (Neil F)
Zevra Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
222.02K
+15.93%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
45.00K
+12.50%
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
Mr. Rahsaan W. Thompson
Mr. Rahsaan W. Thompson
Chief Legal Officer, Secretary, Compliance Officer
Chief Legal Officer, Secretary, Compliance Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
222.02K
+15.93%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
45.00K
+12.50%
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
收入明细
FY2025Q2
FY2024
FY2023
FY2022
FY2021
FY2020
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
United States
25.88M
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.53%
Woodline Partners LP
6.17%
The Vanguard Group, Inc.
5.48%
Adage Capital Management, L.P.
3.95%
Nantahala Capital Management, LLC
3.50%
其他
74.37%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.53%
Woodline Partners LP
6.17%
The Vanguard Group, Inc.
5.48%
Adage Capital Management, L.P.
3.95%
Nantahala Capital Management, LLC
3.50%
其他
74.37%
股东类型
持股股东
占比
Hedge Fund
24.62%
Investment Advisor
24.56%
Investment Advisor/Hedge Fund
16.60%
Research Firm
3.61%
Private Equity
1.62%
Individual Investor
0.80%
Venture Capital
0.33%
Bank and Trust
0.16%
Pension Fund
0.14%
其他
27.57%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
256
37.37M
66.37%
-1.07M
2025Q2
239
33.85M
61.90%
-4.28M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
3.72M
6.62%
-68.78K
-1.82%
Jun 30, 2025
Woodline Partners LP
4.62M
8.22%
+51.00
+0.00%
Jun 30, 2025
The Vanguard Group, Inc.
2.95M
5.26%
+126.84K
+4.49%
Jun 30, 2025
Adage Capital Management, L.P.
4.17M
7.42%
+550.00K
+15.20%
Jun 30, 2025
Nantahala Capital Management, LLC
1.47M
2.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
2.20M
3.92%
+10.59K
+0.48%
Jun 30, 2025
State Street Investment Management (US)
1.24M
2.21%
+65.11K
+5.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.24M
2.21%
+9.28K
+0.75%
Jun 30, 2025
Legal & General Investment Management Ltd.
935.68K
1.67%
+197.94K
+26.83%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Simplify Propel Opportunities ETF
2.21%
State Street SPDR S&P Pharmaceuticals ETF
1.46%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Federated Hermes MDT Small Cap Core ETF
0.19%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
查看更多
Simplify Propel Opportunities ETF
占比2.21%
State Street SPDR S&P Pharmaceuticals ETF
占比1.46%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.04%
Federated Hermes MDT Small Cap Core ETF
占比0.19%
iShares Micro-Cap ETF
占比0.11%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.06%
iShares Biotechnology ETF
占比0.05%
Vanguard US Momentum Factor ETF
占比0.05%
iShares Russell 2000 Growth ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Zevra Therapeutics Inc的前五大股东是谁？
Zevra Therapeutics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：3.72M，占总股份比例：6.62%。
Woodline Partners LP持有股份：4.62M，占总股份比例：8.22%。
The Vanguard Group, Inc.持有股份：2.95M，占总股份比例：5.26%。
Adage Capital Management, L.P.持有股份：4.17M，占总股份比例：7.42%。
Nantahala Capital Management, LLC持有股份：1.47M，占总股份比例：2.62%。
BlackRock Institutional Trust Company, N.A.持有股份：3.72M，占总股份比例：6.62%。
Woodline Partners LP持有股份：4.62M，占总股份比例：8.22%。
The Vanguard Group, Inc.持有股份：2.95M，占总股份比例：5.26%。
Adage Capital Management, L.P.持有股份：4.17M，占总股份比例：7.42%。
Nantahala Capital Management, LLC持有股份：1.47M，占总股份比例：2.62%。
Zevra Therapeutics Inc的前三大股东类型是什么？
Zevra Therapeutics Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
Woodline Partners LP
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Woodline Partners LP
The Vanguard Group, Inc.
有多少机构持有Zevra Therapeutics Inc(ZVRA)的股份？
截至2025Q3，共有256家机构持有Zevra Therapeutics Inc的股份，合计持有的股份价值约为37.37M，占公司总股份的66.37%。与2025Q2相比，机构持股有所增加，增幅为4.47%。
哪个业务部门对Zevra Therapeutics Inc的收入贡献最大？
在FY2025Q2，--业务部门对Zevra Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
